Your request has been received.
We will send you more information as it becomes available.
Effective January 1, 2025: ASP+6% reimbursement for EXPAREL when billing with code J0666 across all outpatient surgical settings.
Superior pain control and reduced opioid consumption through 4 days vs bupivacaine HCl
cumulative pain scores (P<0.0074)
total postsurgical opioid consumption (P<0.0071)
(P=0.0018)
(P=0.0191)
(P=0.0404)
The adductor canal block pivotal trial investigated EXPAREL admixed with bupivacaine HCI versus bupivacaine HCl alone, administered as an adductor canal block (ACB) for total knee arthroplasty (TKA). Prior to the surgical procedure, patients received 133 mg (10 mL) of EXPAREL admixed with 50 mg (10 mL) of 0.5% bupivacaine HCl OR 50 mg (10 mL) of 0.5% bupivacaine HCl mixed with 10 mL normal saline via saphenous nerve (adductor canal) block. All patients also received 37.5 mg (15 mL) of 0.25% immediate-release bupivacaine HCl as an infiltration between the popliteal artery and capsule of the knee (IPACK) block immediately following study drug administration.
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
overall opioid consumption (P<0.005)
cumulative pain scores (P<0.04)
10% with EXPAREL (n=70)
0% with BUPIVACAINE HCI (n=69)
Results from a phase 4, double-blind, randomized, controlled trial that compared the efficacy and safety of EXPAREL 266 mg (20 mL) (n=70) and bupivacaine HCl (n=69) in a TKA study. Primary end points: area under the curve (AUC) of visual analog scale pain intensity scores 12 to 48 hours postsurgery; total opioid consumption 0 to 48 hours postsurgery. Rescue opioids for pain were available upon patient request. Rates and types of adverse events were similar between treatment groups. The most common adverse events were nausea, dizziness, and muscle spasms.
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
TKA, total knee arthroplasty.
Superior pain control and reduced opioid consumption through 4 days vs bupivacaine HCl
cumulative pain scores (P<0.00001)
total postsurgical opioid consumption (P<0.00001)
5x more participants in the EXPAREL group were opioid free through 4 days
The sciatic nerve block in the popliteal fossa pivotal trial investigated EXPAREL versus bupivacaine HCl administered via sciatic nerve block in the popliteal fossa in participants undergoing bunionectomy, a common and well-validated surgical model often used to study postsurgical pain for foot and ankle procedures. Prior to the surgical procedure, patients received 133 mg (10 mL) of EXPAREL mixed with 20 mL saline OR 50 mg (20 mL) of 0.25% bupivacaine HCl mixed with 10 mL saline via sciatic nerve block in the popliteal fossa. All patients received 100 mg (20 mL) of 0.5% immediate-release bupivacaine HCl as a Mayo field block after study drug administration
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
overall opioid consumption (P<0.0001)
cumulative pain scores (P<0.0001)
23% at 24 HOURS (P<0.0001)
13% at 48 hours (P=0.008)
Results from a phase 3, multicenter, controlled trial that compared the postsurgical analgesia efficacy, safety, and pharmacokinetics of EXPAREL 133 mg (10 mL) and placebo in patients undergoing total shoulder arthroplasty or rotator cuff repair. Primary and secondary end points: pain intensity through 48 hours postsurgery, as measured by AUC of VAS pain intensity scores, and total postsurgical opioid consumption.
*Rescue opioids for pain were available upon patient request.
†The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
AUC, area under the curve; ISBP, interscalene brachial plexus; VAS, Visual Analogue Scale.
overall opioid consumption (P<0.0117)â€
overall opioid consumption
Results from a prospective, 13-site, multicenter, randomized clinical trial, EXPAREL significantly improved postsurgical recovery when used in a TAP block after C-section. Primary end point: EXPAREL reduced opioid consumption by 52%, compared with standard bupivacaine, over 72 hours and maintained a significant opioid-minimizing effect over 2 weeks.
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
†The reduction in opioid consumption continued for two weeks postpartum.
TAP, transversus abdominis plane; VAS, Visual Analogue Scale.
45% lower overall opioid consumption (P=0.0006)â€
30% lower cumulative pain scores (P<0.0001)â€
28% with EXPAREL (n=95)
10% with PLACEBO (n=94)
Results from a phase 3, multicenter, randomized double-blind, placebo-controlled trial that evaluated the efficacy of 166 mg (20 mL) of EXPAREL in 186 patients undergoing 2- or 3-column excisional hemorrhoidectomy. Primary end point: cumulative pain score reflected in AUC of numeric rating scale through 72 hours. Placebo was preservative-free saline for injection. Opioid rescue medication (up to 10 mg) of morphine administered intramuscularly) was available to all patients.
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
†Results vs placebo through 72 hours. Opioid reduction calculated based on geometric mean ratio.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.